Catalog No.: PC-49255Not For Human Use, Lab Use Only.
Leriglitazone (MIN-102) is a novel brain penetrant, selective and orally bioavailable PPARγ agonist with EC50 of 9 uM, shows potential best-in-class profile indicated for CNS diseases.
Leriglitazone (MIN-102) is a novel brain penetrant, selective and orally bioavailable PPARγ agonist with EC50 of 9 uM, shows potential best-in-class profile indicated for CNS diseases.
Leriglitazone (MIN-102) increases frataxin levels and mitochondrial markers in FRDA models.
Leriglitazone (MIN-102) protects from neurodegeneration by improving mitochondrial function.
Leriglitazone (MIN-102) prevents lipid droplets formation in frataxin-deficient cardiomyocytes.
Leriglitazone (MIN-102) rescues the motor function deficit of the YG8sR mice.
Leriglitazone (MIN-102) emerges as a potential therapeutic agent for Friedreich Ataxia.
